• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics COVID-19 Classics

The COVE trial: mRNA-1273 vaccine for preventing COVID-19 [Classics Series]

byDeepti Shroff Karhade
July 15, 2022
in COVID-19 Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. In this phase 3 trial, the mRNA-1273 vaccine was found to be efficacious in preventing symptomatic infection from coronavirus disease 2019 (COVID-19) in comparison to a placebo control.

2. All serious cases of COVID-19 occurred in the placebo group and no major safety concerns were identified for the mRNA-1273 vaccine.

Original Date of Publication: February 2021

Study Rundown: The Coronavirus Efficacy (COVE) trial evaluated the efficacy of the mRNA-1273 at preventing symptomatic COVID-19 infection as compared to a placebo injection. The placebo group had significantly higher rates of COVID-19 infection at 14-day follow-up, which was consistent in subgroup analysis of participants with a previous COVID-19 infection and those aged 65 years or older. No cases of severe COVID-19 infection were seen in the intervention group and the incidence of serious adverse events did not differ significantly between groups. The primary limitation of the COVE trial was the short follow-up time for measuring efficacy and adverse events. Although, a two-year follow-up duration is planned for enrolled patients. The COVE trial was the first to demonstrate that the mRNA-1273 vaccine washighly efficacious at preventing COVID-19 infection with a low-risk safety profile for serious adverse events.

Click to read the study in NEJM

In-Depth [randomized control trial]: The participants of the COVE trial received two doses of either the mRNA-1273 vaccine (n = 15 210) or a placebo control injection (n = 15 210) with 28 days between doses and a 14-day follow-up time. The mRNA-1273 vaccine had 95.2% efficacy (95%CI 91.2-97.4) at preventing symptomatic COVID-19 infection as compared to placebo control. Notably, the mRNA-1273 vaccine was found to be 100% efficacious at preventing severe COVID-19 infection. Injection-site adverse events were higher in the mRNA-1273 group after both the first (84.2% versus 19.8%) and second injections (88.6% versus 18.8%). Similarly, systemic adverse reactions were also increased in the intervention group following the first (54.9% versus 42.2%) and second doses (79.4% versus 36.5%). Serious adverse event rates did not differ significantly between the mRNA-1273 and placebo injection groups.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 6

Perfluorohexyloctane drops significantly improve dry eye due to Meibomian gland dysfunction

The Scan by 2 Minute Medicine®: the Future of Medicine, Neuralink, the Spotlight on Celine Dion and COVID-19 on Social Media

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021 Feb 4;384(5):403–16.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adverse eventsCoronavirusmRNA-1273 vaccinephase 3 trial
Previous Post

Incidence and predictors of multimorbidity in a Korean geriatric population

Next Post

The EMPACTA trial: Tocilizumab reduced COVID-19 disease-related adverse health outcomes [Classics Series]

RelatedReports

2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
Adalimumab aids in control of noninfectious uveitis
Ophthalmology

Perfluorohexyloctane drops significantly improve dry eye due to Meibomian gland dysfunction

January 9, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: the Future of Medicine, Neuralink, the Spotlight on Celine Dion and COVID-19 on Social Media

December 27, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Neurology Classics

The OVIVA trial: Oral versus intravenous antibiotics for bone and joint infection [Classics Series]

September 14, 2022
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

The EMPACTA trial: Tocilizumab reduced COVID-19 disease-related adverse health outcomes [Classics Series]

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

10-second one-legged stance performance may predict survival in middle-aged and older individuals

#VisualAbstract: Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery

#VisualAbstract: Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options